Skip to main content
OTCMKTS:DROP

Fuse Science Competitors

$0.03
+0.00 (+2.76 %)
(As of 05/14/2021 03:39 PM ET)
Add
Compare
Today's Range
$0.02
$0.03
50-Day Range
$0.02
$0.04
52-Week Range
$0.00
$0.09
Volume29,750 shs
Average Volume847,553 shs
Market Capitalization$6,854.00
P/E RatioN/A
Dividend YieldN/A
Beta0.28

Competitors

Fuse Science (OTCMKTS:DROP) Vs. IDXX, IPSEY, QDEL, NEOG, NTLA, and RIOT

Should you be buying DROP stock or one of its competitors? Companies in the industry of "diagnostic substances" are considered alternatives and competitors to Fuse Science, including IDEXX Laboratories (IDXX), Ipsen (IPSEY), Quidel (QDEL), Neogen (NEOG), Intellia Therapeutics (NTLA), and Riot Blockchain (RIOT).

IDEXX Laboratories (NASDAQ:IDXX) and Fuse Science (OTCMKTS:DROP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.

Risk and Volatility

IDEXX Laboratories has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Fuse Science has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.

Profitability

This table compares IDEXX Laboratories and Fuse Science's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IDEXX Laboratories19.20%198.91%25.75%
Fuse ScienceN/AN/AN/A

Institutional & Insider Ownership

85.1% of IDEXX Laboratories shares are held by institutional investors. 2.5% of IDEXX Laboratories shares are held by company insiders. Comparatively, 7.2% of Fuse Science shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares IDEXX Laboratories and Fuse Science's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEXX Laboratories$2.41 billion18.78$427.72 million$4.89108.40
Fuse ScienceN/AN/AN/AN/AN/A

IDEXX Laboratories has higher revenue and earnings than Fuse Science.

Analyst Recommendations

This is a summary of recent ratings and price targets for IDEXX Laboratories and Fuse Science, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IDEXX Laboratories00503.00
Fuse Science0000N/A

IDEXX Laboratories presently has a consensus price target of $474.60, indicating a potential downside of 10.46%. Given IDEXX Laboratories' higher possible upside, equities analysts plainly believe IDEXX Laboratories is more favorable than Fuse Science.

Summary

IDEXX Laboratories beats Fuse Science on 8 of the 9 factors compared between the two stocks.

Ipsen (OTCMKTS:IPSEY) and Fuse Science (OTCMKTS:DROP) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Profitability

This table compares Ipsen and Fuse Science's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IpsenN/AN/AN/A
Fuse ScienceN/AN/AN/A

Volatility & Risk

Ipsen has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Fuse Science has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Ipsen and Fuse Science, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ipsen05402.44
Fuse Science0000N/A

Earnings & Valuation

This table compares Ipsen and Fuse Science's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ipsen$3.02 billion2.77$-56,780,000.00$1.8913.17
Fuse ScienceN/AN/AN/AN/AN/A

Fuse Science has lower revenue, but higher earnings than Ipsen.

Summary

Ipsen beats Fuse Science on 3 of the 3 factors compared between the two stocks.

Fuse Science (OTCMKTS:DROP) and Quidel (NASDAQ:QDEL) are both consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Fuse Science and Quidel, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fuse Science0000N/A
Quidel10302.50

Quidel has a consensus price target of $182.75, indicating a potential upside of 54.60%. Given Quidel's higher possible upside, analysts plainly believe Quidel is more favorable than Fuse Science.

Insider & Institutional Ownership

84.0% of Quidel shares are held by institutional investors. 7.2% of Fuse Science shares are held by insiders. Comparatively, 14.1% of Quidel shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Fuse Science and Quidel's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fuse ScienceN/AN/AN/AN/AN/A
Quidel$534.89 million9.40$72.92 million$2.7343.30

Quidel has higher revenue and earnings than Fuse Science.

Risk & Volatility

Fuse Science has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Profitability

This table compares Fuse Science and Quidel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fuse ScienceN/AN/AN/A
Quidel36.91%63.31%40.55%

Summary

Quidel beats Fuse Science on 9 of the 9 factors compared between the two stocks.

Fuse Science (OTCMKTS:DROP) and Neogen (NASDAQ:NEOG) are both consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Institutional and Insider Ownership

92.8% of Neogen shares are owned by institutional investors. 7.2% of Fuse Science shares are owned by company insiders. Comparatively, 0.9% of Neogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Fuse Science and Neogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fuse ScienceN/AN/AN/A
Neogen13.92%8.13%7.45%

Volatility and Risk

Fuse Science has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Neogen has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.

Earnings & Valuation

This table compares Fuse Science and Neogen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fuse ScienceN/AN/AN/AN/AN/A
Neogen$418.17 million11.88$59.47 million$1.1382.18

Neogen has higher revenue and earnings than Fuse Science.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Fuse Science and Neogen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fuse Science0000N/A
Neogen02102.33

Neogen has a consensus price target of $81.50, indicating a potential downside of 12.23%. Given Neogen's higher possible upside, analysts clearly believe Neogen is more favorable than Fuse Science.

Summary

Neogen beats Fuse Science on 8 of the 9 factors compared between the two stocks.

Fuse Science (OTCMKTS:DROP) and Intellia Therapeutics (NASDAQ:NTLA) are both consumer staples companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Fuse Science and Intellia Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fuse ScienceN/AN/AN/AN/AN/A
Intellia Therapeutics$43.10 million106.01$-99,530,000.00($2.11)-31.77

Fuse Science has higher earnings, but lower revenue than Intellia Therapeutics.

Profitability

This table compares Fuse Science and Intellia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fuse ScienceN/AN/AN/A
Intellia Therapeutics-193.01%-40.14%-30.11%

Institutional and Insider Ownership

95.6% of Intellia Therapeutics shares are held by institutional investors. 7.2% of Fuse Science shares are held by insiders. Comparatively, 4.1% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Fuse Science has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Fuse Science and Intellia Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fuse Science0000N/A
Intellia Therapeutics041102.73

Intellia Therapeutics has a consensus price target of $67.5385, suggesting a potential upside of 0.74%. Given Intellia Therapeutics' higher possible upside, analysts plainly believe Intellia Therapeutics is more favorable than Fuse Science.

Summary

Intellia Therapeutics beats Fuse Science on 5 of the 9 factors compared between the two stocks.

Riot Blockchain (NASDAQ:RIOT) and Fuse Science (OTCMKTS:DROP) are both business services companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Analyst Recommendations

This is a summary of current ratings and target prices for Riot Blockchain and Fuse Science, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Riot Blockchain00103.00
Fuse Science0000N/A

Riot Blockchain currently has a consensus target price of $64.00, suggesting a potential upside of 145.96%. Given Riot Blockchain's higher possible upside, equities analysts clearly believe Riot Blockchain is more favorable than Fuse Science.

Valuation & Earnings

This table compares Riot Blockchain and Fuse Science's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Riot Blockchain$6.84 million320.10$-20,040,000.00($0.73)-35.64
Fuse ScienceN/AN/AN/AN/AN/A

Fuse Science has lower revenue, but higher earnings than Riot Blockchain.

Profitability

This table compares Riot Blockchain and Fuse Science's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Riot Blockchain-250.06%-51.38%-47.50%
Fuse ScienceN/AN/AN/A

Volatility and Risk

Riot Blockchain has a beta of 4.56, indicating that its stock price is 356% more volatile than the S&P 500. Comparatively, Fuse Science has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.

Institutional and Insider Ownership

9.0% of Riot Blockchain shares are held by institutional investors. 3.5% of Riot Blockchain shares are held by company insiders. Comparatively, 7.2% of Fuse Science shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Riot Blockchain beats Fuse Science on 5 of the 9 factors compared between the two stocks.


Fuse Science Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$530.07+2.3%$45.20 billion$2.41 billion92.35Insider Selling
Ipsen logo
IPSEY
Ipsen
0.8$24.89+1.8%$8.34 billion$3.02 billion13.17
Quidel logo
QDEL
Quidel
2.4$118.21+1.4%$5.03 billion$534.89 million13.87Analyst Report
Insider Selling
Neogen logo
NEOG
Neogen
1.2$92.86+0.8%$4.97 billion$418.17 million81.46Stock Split
Intellia Therapeutics logo
NTLA
Intellia Therapeutics
1.1$67.04+9.2%$4.57 billion$43.10 million-29.40Analyst Upgrade
Gap Down
Riot Blockchain logo
RIOT
Riot Blockchain
1.3$26.02+14.6%$2.19 billion$6.84 million-43.37Upcoming Earnings
News Coverage
Gap Down
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.38+6.3%$2.11 billion$638.60 million-10.53Gap Down
Heska logo
HSKA
Heska
1.4$192.40+2.8%$2.01 billion$122.66 million-86.67
Lantheus logo
LNTH
Lantheus
1.9$21.12+1.7%$1.43 billion$347.34 million264.03Analyst Report
Gap Down
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$27.09+7.7%$1.07 billion$3.57 million-12.15Gap Down
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$19.07+2.5%$826.30 million$253.67 million17.66Analyst Revision
Aspira Women's Health logo
AWH
Aspira Women's Health
1.4$5.11+5.1%$572.04 million$4.54 million-34.07Earnings Announcement
News Coverage
Quotient logo
QTNT
Quotient
1.6$3.66+3.6%$370.15 million$32.66 million-3.10Gap Down
OncoCyte logo
OCX
OncoCyte
1.7$3.90+1.8%$346.32 millionN/A-7.49Upcoming Earnings
VolitionRx logo
VNRX
VolitionRx
1.2$3.41+11.7%$180.37 million$17.10 million-7.75Earnings Announcement
Gap Down
Nymox Pharmaceutical logo
NYMX
Nymox Pharmaceutical
0.8$1.72+1.7%$135.38 million$120,000.00-9.56
ICCC
ImmuCell
1.3$9.65+4.6%$74.65 million$13.72 million-41.96Earnings Announcement
News Coverage
Gap Down
Trinity Biotech logo
TRIB
Trinity Biotech
0.5$3.40+1.2%$71.07 million$90.43 million-5.86News Coverage
Gap Down
Achieve Life Sciences logo
ACHV
Achieve Life Sciences
1.5$9.41+4.4%$57.87 millionN/A-0.85Earnings Announcement
News Coverage
Akers Biosciences logo
AKER
Akers Biosciences
0.7$3.39+7.4%$56.45 million$1.58 million0.00Upcoming Earnings
Gap Up
ABIO
ARCA biopharma
0.9$3.23+5.0%$46.54 millionN/A-1.25Earnings Announcement
Gap Down
Navidea Biopharmaceuticals logo
NAVB
Navidea Biopharmaceuticals
1.7$1.60+2.5%$45.71 million$660,000.00-3.08Earnings Announcement
Gap Down
Biomerica logo
BMRA
Biomerica
1.3$3.55+1.4%$43.67 million$6.69 million-8.88
StageZero Life Sciences logo
GNWSF
StageZero Life Sciences
0.5$0.56+14.4%$33.58 million$140,000.00-2.14Upcoming Earnings
News Coverage
Gap Down
GNWSD
StageZero Life Sciences
0.0$0.47+14.8%$23.19 million$140,000.000.00High Trading Volume
Gap Up
BG Medicine logo
BGMD
BG Medicine
0.5$0.08+0.0%$840,000.00N/A0.00
RGDXQ
Response Genetics
0.5$0.01+0.0%$461,000.00N/A0.00Gap Down
FluoroPharma Medical logo
FPMI
FluoroPharma Medical
0.6$0.01+0.0%$253,000.00N/A0.00News Coverage
Gap Up
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.